← Back to Clinical Trials
Recruiting NCT03886961

NCT03886961 The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03886961
Status Recruiting
Phase
Sponsor University of Florida
Condition Lung Transplant
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2019-05-17
Primary Completion 2027-03-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Reflux Band

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2019-05-17 with a primary completion date of 2027-03-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.

Eligibility Criteria

Inclusion Criteria: * Clinically stable lung transplant patients(single lung, double lung, or re-transplant) as defined by stable FEV1 over the prior two visits * 13 Abnormal pH impedence or esophagram or documented gastric reflux at pre-transplant evaluation * Patient must be willing and able to provide informed consent * Understands the clinical study requirements and is able to comply with follow-up schedule Exclusion Criteria: * Currently being treated with another investigational medical device and/or drug * Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP) * Previous head or neck surgery / radiation * Carotid artery disease, thyroid disease, or history of cerebral vascular disease * Nasopharyngeal cancer * Suspected esophageal cancer

Contact & Investigator

Central Contact

Vanessa Scheuble

✉ Vanessa.Scheuble@medicine.ufl.edu

📞 352-273-7589

Principal Investigator

Manuel Amaris, MD

PRINCIPAL INVESTIGATOR

University of Florida

Frequently Asked Questions

Who can join the NCT03886961 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03886961 currently recruiting?

Yes, NCT03886961 is actively recruiting participants. Contact the research team at Vanessa.Scheuble@medicine.ufl.edu for enrollment information.

Where is the NCT03886961 trial being conducted?

This trial is being conducted at Gainesville, United States.

Who is sponsoring the NCT03886961 clinical trial?

NCT03886961 is sponsored by University of Florida. The principal investigator is Manuel Amaris, MD at University of Florida. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology